BioCryst plans $100M stock offering

Posted by David Bracken on May 28, 2014 

BioCryst Pharmaceuticals announced this week that it is planning to sell $100 million in stock in a public offering.

The proceeds are to be used for general corporate purposes and to fund the development of BCX4161, the Durham drug developer’s oral treatment for angioedema, a rare disease that results in swelling and painful welts.

BioCryst’s stock rose 11 percent on Tuesday after the company reported positive Phase 2 trial results for BCX4161.

BioCryst has no products on the U.S. market. It is also developing peramivir, an influenza treatment.

Earlier this month the company’s stock fell 14 percent after it reported another potential setback for peramivir.

A Food and Drug Administration inspection raised a "number of concerns" about the contract manufacturer that was to produce the treatment.

BioCryst’s stock sale is a so-called “shelf” registration process that allows the company to sell any combination of securities for a total sum of $100 million.

BioCryst’s shares, which opened at $9.99, were down about 20 cents in mid-day trading Wednesday.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service